Victoria V. Titova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Victoria V. Titova has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Tatiana Yu. Demidova
Pirogov Russian National Research Medical University
20 shared publications - A. S. Teplova
Pirogov Russian National Research Medical University
4 shared publications Pirogov Russian National Research Medical University
3 shared publications- Fatima O. Ushanova
Pirogov Russian National Research Medical University
2 shared publications Kh. M. Muslimova
Pirogov Russian National Research Medical University
2 shared publications- M. Ya. Izmailova
Pirogov Russian National Research Medical University
2 shared publications
Latest Publications
- 3 May 2026
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 7 (1) , 48-57
Phenotypic and genetic clusters of type 2 diabetes mellitus: Associations with complication risk and therapeutic strategies
Type 2 diabetes mellitus (T2DM) is one of the most common noncommunicable diseases of our time, reaching global pandemic proportions. Despite significant advances in understanding the pathogenesis of the disease and the emergence of new classes of hypoglycemic medications, the effectiveness of T2DM prevention and treatment remains limited, resulting in high rates of disability and mortality due to micro- and macrovascular complications. A key challenge hindering the development of optimal therapeutic strategies is the marked heterogeneity of T2DM. The disease is not a single nosological entity, but rather a syndrome encompassing a multitude of different pathological conditions characterized by chronic hyperglycemia but differing in etiology, pathophysiological mechanisms, clinical presentation, rate of progression, and spectrum of complications. In recent years, methods for stratifying T2DM based on cluster analysis of clinical and genetic data have been actively developed. A fundamental study by Ahlqvist E. et al. identified five T2DM subtypes that differ in pathogenesis, progression, and risk of complications. Concurrently, the development of genome-wide association studies (GWAS) and machine learning methods (Bayesian nonnegative matrix factorization, soft clustering) has enabled the grouping of hundreds of genetic loci into physiological clusters corresponding to β-cell dysfunction, obesity, lipodystrophy, and lipid metabolism disorders. Stable associations have been established between the identified subtypes and outcomes, including the risk of retinopathy, nephropathy, and cardiovascular events. The integration of phenotypic and genetic clustering opens up prospects for the development of pathogenetically based therapeutic strategies: early insulin administration in insulin-deficient clusters, prioritization of SGLT2 inhibitors and GLP-1 receptor agonists in the insulin-resistant cluster, a focus on weight loss in obesity clusters, and minimization of the risk of hypoglycemia in age-related diabetes.
- 3 May 2026
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 7 (1) , 48-57
Phenotypic and genetic clusters of type 2 diabetes mellitus: Associations with complication risk and therapeutic strategies
Type 2 diabetes mellitus (T2DM) is one of the most common noncommunicable diseases of our time, reaching global pandemic proportions. Despite significant advances in understanding the pathogenesis of the disease and the emergence of new classes of hypoglycemic medications, the effectiveness of T2DM prevention and treatment remains limited, resulting in high rates of disability and mortality due to micro- and macrovascular complications. A key challenge hindering the development of optimal therapeutic strategies is the marked heterogeneity of T2DM. The disease is not a single nosological entity, but rather a syndrome encompassing a multitude of different pathological conditions characterized by chronic hyperglycemia but differing in etiology, pathophysiological mechanisms, clinical presentation, rate of progression, and spectrum of complications. In recent years, methods for stratifying T2DM based on cluster analysis of clinical and genetic data have been actively developed. A fundamental study by Ahlqvist E. et al. identified five T2DM subtypes that differ in pathogenesis, progression, and risk of complications. Concurrently, the development of genome-wide association studies (GWAS) and machine learning methods (Bayesian nonnegative matrix factorization, soft clustering) has enabled the grouping of hundreds of genetic loci into physiological clusters corresponding to β-cell dysfunction, obesity, lipodystrophy, and lipid metabolism disorders. Stable associations have been established between the identified subtypes and outcomes, including the risk of retinopathy, nephropathy, and cardiovascular events. The integration of phenotypic and genetic clustering opens up prospects for the development of pathogenetically based therapeutic strategies: early insulin administration in insulin-deficient clusters, prioritization of SGLT2 inhibitors and GLP-1 receptor agonists in the insulin-resistant cluster, a focus on weight loss in obesity clusters, and minimization of the risk of hypoglycemia in age-related diabetes.
- 27 December 2025
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 6 (4) , 12-18
Comparative characteristics of Limb Rescue Center patients with diabetic foot syndrome and type 1 and type 2 diabetes mellitus
Diabetic foot syndrome (DFS) is a significant medical and social problem. Despite modern prevention and treatment options, as well as patient routing, DFS remains one of the dominant causes of lower limb amputation and leads to disability in patients with both type 1 (DM1) and type 2 (DM2) diabetes mellitus. The aim . To compare the clinical and laboratory characteristics of patients with DM1 (n = 30) and DM2 (n = 729) hospitalized at the Limb Rescue Center of the V.P. Demikhov State Clinical Hospital in the period from 2019 to 2020. Materials and methods . Anamnestic and clinical laboratory data from 759 electronic medical records of patients of the limb rescue center, patients with DM1 or DM2, were analyzed. Results . The majority of patients with DM1 were 45–60 years old – 56.67% (n = 17), with DM2 – elderly (50.75%, n = 370). The median fasting plasma glucose upon admission in patients with DM1 was 11.5 [6.2; 14.7] mmol/L, in patients with DM2 – 9.9 [7.2; 13.8] mmol/L. The average HbA1c in group 1 was 8.71 ± 0.26 (95% CI: 8.18 – 9.25 in patients with DM2 – 7.8 [6.7; 9.1]%. The mean GFR was 65.92 ± 3.43 (95% CI: 58.88 – 60.57) ml/min/1.73 m 2 and 63.38 ± 0.90 (95% CI: 61.62 – 65.15) ml/min/1.73 m 2 , respectively, in groups 1 and 2. The structure of ulcerative necrotic lesions in patients with DM1 was dominated by ulcer (33.33%, n = 10) and purulent/purulent-destructive arthritis (26.6%, n = 8), and in patients with DM2 - gangrene (33.47%, n = 244) and ulcer (25.1%, n = 183). Amputation occurred in 36.67% (n = 11) of patients with DM1 and in 24.3% (n = 372) of patients with DM2. Conclusions . The identified features of patients with DFS and DM1 and DM2, along with the data obtained on the relatively high frequency of amputations in both groups, indicate the need to optimize patient routing algorithms and increase the attention of patients with both DM1 and DM2 to the importance of foot care and regular visits to the diabetic foot office.
- 27 December 2025
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 6 (4) , 12-18
Comparative characteristics of Limb Rescue Center patients with diabetic foot syndrome and type 1 and type 2 diabetes mellitus
Diabetic foot syndrome (DFS) is a significant medical and social problem. Despite modern prevention and treatment options, as well as patient routing, DFS remains one of the dominant causes of lower limb amputation and leads to disability in patients with both type 1 (DM1) and type 2 (DM2) diabetes mellitus. The aim . To compare the clinical and laboratory characteristics of patients with DM1 (n = 30) and DM2 (n = 729) hospitalized at the Limb Rescue Center of the V.P. Demikhov State Clinical Hospital in the period from 2019 to 2020. Materials and methods . Anamnestic and clinical laboratory data from 759 electronic medical records of patients of the limb rescue center, patients with DM1 or DM2, were analyzed. Results . The majority of patients with DM1 were 45–60 years old – 56.67% (n = 17), with DM2 – elderly (50.75%, n = 370). The median fasting plasma glucose upon admission in patients with DM1 was 11.5 [6.2; 14.7] mmol/L, in patients with DM2 – 9.9 [7.2; 13.8] mmol/L. The average HbA1c in group 1 was 8.71 ± 0.26 (95% CI: 8.18 – 9.25 in patients with DM2 – 7.8 [6.7; 9.1]%. The mean GFR was 65.92 ± 3.43 (95% CI: 58.88 – 60.57) ml/min/1.73 m 2 and 63.38 ± 0.90 (95% CI: 61.62 – 65.15) ml/min/1.73 m 2 , respectively, in groups 1 and 2. The structure of ulcerative necrotic lesions in patients with DM1 was dominated by ulcer (33.33%, n = 10) and purulent/purulent-destructive arthritis (26.6%, n = 8), and in patients with DM2 - gangrene (33.47%, n = 244) and ulcer (25.1%, n = 183). Amputation occurred in 36.67% (n = 11) of patients with DM1 and in 24.3% (n = 372) of patients with DM2. Conclusions . The identified features of patients with DFS and DM1 and DM2, along with the data obtained on the relatively high frequency of amputations in both groups, indicate the need to optimize patient routing algorithms and increase the attention of patients with both DM1 and DM2 to the importance of foot care and regular visits to the diabetic foot office.
- 20 November 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 238-250
Metabolic dysfunction-associated steatotic liver disease: Role in the development of comorbid conditions and therapeutic management
The rising prevalence of overweight and obesity has grown into a global epidemic, which entailed the increased incidence of associated metabolic disorders. Metabolic dysfunction-associated steatotic liver disease (MASLD) ranks highest among them. It is recognized as the most common chronic liver disease worldwide, affecting approximately 38% of the global population, by various estimates. MASLD represents a range of conditions including simple steatosis, metabolically associated steatohepatitis, fibrosis, and cirrhosis. The significance of MASLD is caused by not only its high prevalence, but also by its essential impact on overall morbidity and mortality rates. This disease is associated with an increased risk of developing type 2 diabetes, cardiovascular disease, chronic kidney disease, and certain malignancies. Moreover, the leading cause of death in patients with MASLD is not liver-related but cardiovascular complications, which emphasises the systemic nature of the metabolic abnormalities underlying its pathogenesis. Modern diagnostic techniques of the disease are increasingly shifting towards noninvasive methods allowing to evaluate the severity of steatosis and liver fibrosis, which is particularly important for screening and case follow-up in settings where the disease affects a large number of people. MASLD management strategies remain under active development. While lifestyle modification remains the mainstay of treatment, the drug therapy, including both metabolic agents and hepatotropic drugs such as essential phospholipids, continually gains in importance. The emergence of new drugs that specifically target the key components of pathogenesis opens up potential for pathogenetic therapy and improvement of long-term outcomes. This review is aimed to analyse the present-day ideas of the diagnosis, pathogenesis, and promising directions of MASLD treatment, as well as to assess the role of different classes of drugs, including essential phospholipids, in the comprehensive management of patients with this disease.
- 20 November 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 238-250
Metabolic dysfunction-associated steatotic liver disease: Role in the development of comorbid conditions and therapeutic management
The rising prevalence of overweight and obesity has grown into a global epidemic, which entailed the increased incidence of associated metabolic disorders. Metabolic dysfunction-associated steatotic liver disease (MASLD) ranks highest among them. It is recognized as the most common chronic liver disease worldwide, affecting approximately 38% of the global population, by various estimates. MASLD represents a range of conditions including simple steatosis, metabolically associated steatohepatitis, fibrosis, and cirrhosis. The significance of MASLD is caused by not only its high prevalence, but also by its essential impact on overall morbidity and mortality rates. This disease is associated with an increased risk of developing type 2 diabetes, cardiovascular disease, chronic kidney disease, and certain malignancies. Moreover, the leading cause of death in patients with MASLD is not liver-related but cardiovascular complications, which emphasises the systemic nature of the metabolic abnormalities underlying its pathogenesis. Modern diagnostic techniques of the disease are increasingly shifting towards noninvasive methods allowing to evaluate the severity of steatosis and liver fibrosis, which is particularly important for screening and case follow-up in settings where the disease affects a large number of people. MASLD management strategies remain under active development. While lifestyle modification remains the mainstay of treatment, the drug therapy, including both metabolic agents and hepatotropic drugs such as essential phospholipids, continually gains in importance. The emergence of new drugs that specifically target the key components of pathogenesis opens up potential for pathogenetic therapy and improvement of long-term outcomes. This review is aimed to analyse the present-day ideas of the diagnosis, pathogenesis, and promising directions of MASLD treatment, as well as to assess the role of different classes of drugs, including essential phospholipids, in the comprehensive management of patients with this disease.
- Open Access
- 13 November 2025
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 6 (3) , 86-95
Modification of the gut microbiome in response to metformin and other antidiabetic drugs
Currently, there is a rapid increase in the study of the relationship of the gut microbiota (GM) with the pharmacokinetics and pharmacodynamics of drugs, including hypoglycemic ones. The review describes possible mechanisms by which GM can influence the efficacy and safety of various hypoglycemic drugs (HDs). Moreover, intestinal bacteria affecting the pharmacokinetics of HDs are described. Despite the fact that data on the relationship of GM with the effectiveness and development of side effects of HDs are sharply limited, using the example of metformin, it was determined that the presence in GM of a high number of Short-chain fatty acids (SCFAs) producers and genera associated with bile acid metabolism is associated with high drug efficacy and the development of side effects. The fact is that SCFAs and primary bile acids are triggers for the secretion of glucagon-like peptide-1, which, on the one hand, contributes to the improvement of glycemic indices through the incretin effect and the operation of the “intestine – brain – perif” mechanism.
- 13 November 2025
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 6 (3) , 86-95
Open AccessModification of the gut microbiome in response to metformin and other antidiabetic drugs
Currently, there is a rapid increase in the study of the relationship of the gut microbiota (GM) with the pharmacokinetics and pharmacodynamics of drugs, including hypoglycemic ones. The review describes possible mechanisms by which GM can influence the efficacy and safety of various hypoglycemic drugs (HDs). Moreover, intestinal bacteria affecting the pharmacokinetics of HDs are described. Despite the fact that data on the relationship of GM with the effectiveness and development of side effects of HDs are sharply limited, using the example of metformin, it was determined that the presence in GM of a high number of Short-chain fatty acids (SCFAs) producers and genera associated with bile acid metabolism is associated with high drug efficacy and the development of side effects. The fact is that SCFAs and primary bile acids are triggers for the secretion of glucagon-like peptide-1, which, on the one hand, contributes to the improvement of glycemic indices through the incretin effect and the operation of the “intestine – brain – perif” mechanism.
- Open Access
- 11 November 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (10) , 883-889
Ultra-fast acting insulin analogs: superiority in the treatment of diabetes type 1 and type 2. A review
Ultra-fast acting insulin analogs were created to achieve a physiological profile of action with more rapid and pronounced initial insulin peak. The accelerated absorption of ultra-fast-acting insulin analogues results in a more rapid onset of action, with insulin concentrations reaching their peak in the bloodstream earlier compared to rapid-acting insulin analogues. This rapid peak of insulin action better matches the postprandial glucose absorption profile, resulting in improved glycemic control and a reduced risk of postprandial hyperglycemia. Thus, the rapid onset and offset of action of ultra-rapid-acting insulin analogues provides greater flexibility in adjusting insulin doses based on the carbohydrate content of meals and physical activity levels. A shorter duration of action allows for a reduction in the frequency of hypoglycemic events, which may improve overall quality of life and reduce the fear of hypoglycemia, which is a serious problem for many patients with diabetes. The use of ultra-fast-acting insulin analogues has shown its effectiveness in compensating postprandial hyperglycemia and reducing glucose variability in various patient groups, including patients with type 1 and type 2 diabetes, children and pregnant women, in addition, their use in closed-loop systems has promising results in improving glycemic outcomes.
- 11 November 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (10) , 883-889
Open AccessUltra-fast acting insulin analogs: superiority in the treatment of diabetes type 1 and type 2. A review
Ultra-fast acting insulin analogs were created to achieve a physiological profile of action with more rapid and pronounced initial insulin peak. The accelerated absorption of ultra-fast-acting insulin analogues results in a more rapid onset of action, with insulin concentrations reaching their peak in the bloodstream earlier compared to rapid-acting insulin analogues. This rapid peak of insulin action better matches the postprandial glucose absorption profile, resulting in improved glycemic control and a reduced risk of postprandial hyperglycemia. Thus, the rapid onset and offset of action of ultra-rapid-acting insulin analogues provides greater flexibility in adjusting insulin doses based on the carbohydrate content of meals and physical activity levels. A shorter duration of action allows for a reduction in the frequency of hypoglycemic events, which may improve overall quality of life and reduce the fear of hypoglycemia, which is a serious problem for many patients with diabetes. The use of ultra-fast-acting insulin analogues has shown its effectiveness in compensating postprandial hyperglycemia and reducing glucose variability in various patient groups, including patients with type 1 and type 2 diabetes, children and pregnant women, in addition, their use in closed-loop systems has promising results in improving glycemic outcomes.
- Open Access
- 24 May 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 6,p. 67-74
The value of genome-wide association studies and genetic risk scales for predicting type 2 diabetes mellitus, its complications, and pharmacogenetics
Type 2 diabetes (T2D) is a complex, heritable metabolic disorder characterized by dysregulated glucose homeostasis arising from impaired insulin secretion and insulin resistance. Genome-wide association studies (GWAS) have successfully pinpointed hundreds of genetic loci associated with type 2 diabetes risk, implicating numerous genes in its pathogenesis. Genetic risk assessment can help to predict disease progression and identify at-risk populations where preventive interventions, including lifestyle modification, could be more effective. In addition, identification of patients at high risk of developing T2D will allow for earlier diagnosis and effective treatment at the stage of minimal disorders of carbohydrate metabolism. Better understanding of the pathogenesis of the disease based on knowledge of the functions of genes associated with T2D may help in the development of new drugs to control carbohydrate metabolism. In perespective, the translation of genetic data into clinical applications holds immense potential for advancing type 2 diabetes management, including the development of novel therapeutics and risk prediction strategies. This review explores recent advances in the genomics of type 2 diabetes, highlighting ongoing initiatives to promote precision health. We discuss the use of genetic data in predicting the risk of developing diabetes and its complications, as well as in predicting individual responses to medications and lifestyle interventions.
- 24 May 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 6,p. 67-74
Open AccessThe value of genome-wide association studies and genetic risk scales for predicting type 2 diabetes mellitus, its complications, and pharmacogenetics
Type 2 diabetes (T2D) is a complex, heritable metabolic disorder characterized by dysregulated glucose homeostasis arising from impaired insulin secretion and insulin resistance. Genome-wide association studies (GWAS) have successfully pinpointed hundreds of genetic loci associated with type 2 diabetes risk, implicating numerous genes in its pathogenesis. Genetic risk assessment can help to predict disease progression and identify at-risk populations where preventive interventions, including lifestyle modification, could be more effective. In addition, identification of patients at high risk of developing T2D will allow for earlier diagnosis and effective treatment at the stage of minimal disorders of carbohydrate metabolism. Better understanding of the pathogenesis of the disease based on knowledge of the functions of genes associated with T2D may help in the development of new drugs to control carbohydrate metabolism. In perespective, the translation of genetic data into clinical applications holds immense potential for advancing type 2 diabetes management, including the development of novel therapeutics and risk prediction strategies. This review explores recent advances in the genomics of type 2 diabetes, highlighting ongoing initiatives to promote precision health. We discuss the use of genetic data in predicting the risk of developing diabetes and its complications, as well as in predicting individual responses to medications and lifestyle interventions.
- Open Access
- 16 May 2025
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 6 (1) , 64-74
Using flash glucose monitoring as a tool to achieve compensation of carbohydrate metabolism in a patient with type 2 diabetes mellitus
In recent years, significant progress has been made in glucose monitoring technologies, which allow patients with type 2 diabetes mellitus (T2DM) to more accurately monitor glucose levels and respond quickly to changes. The use of new technologies in the treatment of T2DM, including flash monitoring of glycemia (FMG), helps to select the appropriate hypoglycemic therapy for a particular patient, as well as motivate them to lifestyle changes. In the presented clinical case, a patient with T2DM received basic bolus insulin therapy, however, against its background, compensation for carbohydrate metabolism was not achieved. To assess the causes of hyperglycemia, select and optimize hypoglycemic therapy, as well as motivate the patient to treat diabetes, an FMG system was installed for the patient. Against the background of monitoring, the patient began to calculate the dose of ultrashort-acting insulin, taking into account the bread units consumed, changed his diet, which allowed him to reach the target glucose values as soon as possible, after which the ultrashort-acting insulin was discontinued and metformin was added to therapy. Thus, the patient's commitment to therapy and lifestyle changes during FMG helped to achieve compensation for T2DM. This clinical case demonstrates the importance of using modern glucose monitoring technologies, as well as a combination of various treatment methods to achieve target blood glucose levels in patients with T2DM.
- 16 May 2025
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 6 (1) , 64-74
Open AccessUsing flash glucose monitoring as a tool to achieve compensation of carbohydrate metabolism in a patient with type 2 diabetes mellitus
In recent years, significant progress has been made in glucose monitoring technologies, which allow patients with type 2 diabetes mellitus (T2DM) to more accurately monitor glucose levels and respond quickly to changes. The use of new technologies in the treatment of T2DM, including flash monitoring of glycemia (FMG), helps to select the appropriate hypoglycemic therapy for a particular patient, as well as motivate them to lifestyle changes. In the presented clinical case, a patient with T2DM received basic bolus insulin therapy, however, against its background, compensation for carbohydrate metabolism was not achieved. To assess the causes of hyperglycemia, select and optimize hypoglycemic therapy, as well as motivate the patient to treat diabetes, an FMG system was installed for the patient. Against the background of monitoring, the patient began to calculate the dose of ultrashort-acting insulin, taking into account the bread units consumed, changed his diet, which allowed him to reach the target glucose values as soon as possible, after which the ultrashort-acting insulin was discontinued and metformin was added to therapy. Thus, the patient's commitment to therapy and lifestyle changes during FMG helped to achieve compensation for T2DM. This clinical case demonstrates the importance of using modern glucose monitoring technologies, as well as a combination of various treatment methods to achieve target blood glucose levels in patients with T2DM.
- Open Access
- 13 May 2024
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 5 (2) , 52-61
Review of data on comparative pharmacokinetics, pharmacodynamics, efficacy and safety of the superfast insulin drug lispro
Diabetes mellitus remains one of the main socially significant health problems worldwide. Glycemic control plays a key role in the prevention of all complications of diabetes mellitus. One of the most important factors in the overall control of glycemia in patients with both type 1 and type 2 diabetes mellitus is postprandial glucose levels, as a leading risk factor for delayed vascular complications. Modern possibilities for controlling postprandial glycemia include the use of not only ultrashort insulin preparations, but also ultrafast action. One of the superfast insulin preparations available today is the drug Lumzhev ® (inLisFast), which contains lyspro insulin as an active ingredient. A number of studies on the comparative pharmacokinetics and pharmacodynamics of inLisFast compared with insulin lispro consistently demonstrate a shift in the pharmacokinetic and pharmacodynamic profile to the left, which indicates faster absorption, an increase in early insulin exposure and a decrease in late insulin exposure. inLisFast provides flexibility in the regulation of food intake, which can play a significant role in optimizing glycemic control and improving the quality of life of patients with diabetes.
- 13 May 2024
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 5 (2) , 52-61
Open AccessReview of data on comparative pharmacokinetics, pharmacodynamics, efficacy and safety of the superfast insulin drug lispro
Diabetes mellitus remains one of the main socially significant health problems worldwide. Glycemic control plays a key role in the prevention of all complications of diabetes mellitus. One of the most important factors in the overall control of glycemia in patients with both type 1 and type 2 diabetes mellitus is postprandial glucose levels, as a leading risk factor for delayed vascular complications. Modern possibilities for controlling postprandial glycemia include the use of not only ultrashort insulin preparations, but also ultrafast action. One of the superfast insulin preparations available today is the drug Lumzhev ® (inLisFast), which contains lyspro insulin as an active ingredient. A number of studies on the comparative pharmacokinetics and pharmacodynamics of inLisFast compared with insulin lispro consistently demonstrate a shift in the pharmacokinetic and pharmacodynamic profile to the left, which indicates faster absorption, an increase in early insulin exposure and a decrease in late insulin exposure. inLisFast provides flexibility in the regulation of food intake, which can play a significant role in optimizing glycemic control and improving the quality of life of patients with diabetes.
- Open Access
- 13 May 2024
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 5 (2) , 76-80
Amiodarone-induced thyrotoxicosis type 2: the role of differential diagnosis in patient management
The antiarrhythmic drug amiodarone can affect the function of the thyroid gland, contributing to the development of thyrotoxicosis or hypothyroidism. The development of thyrotoxicosis exacerbates the cardiovascular pathology present in patients: it leads to the progression of left ventricular dysfunction, recurrence of rhythm disturbances, increasing the risk of adverse outcomes. Timely diagnosis of thyrotoxicosis in the treatment of amiodarone is of fundamental importance in choosing the right therapeutic tactics, which is determined by the type of amiodarone-induced thyrotoxicosis (AmIT), the state of the cardiovascular system, and the risk of recurrent arrhythmias. In type 1 AMIT, the main method of controlling the relief of thyrotoxicosis is thyroostatic therapy with the possibility of subsequent radical treatment (radioiodine therapy, thyroidectomy). Type 2 AmIT is a self-limiting process, however, for the treatment of patients with moderate to severe amiodarone-induced thyrotoxicosis type 2, glucocorticoids are the first-line drugs. With a mixed version of AmIT, a combination of antithyroid drugs and glucocorticoids is recommended. This review presents a clinical case of a patient with type 2 AmIT who was treated with thyrostatic drugs for a long time without achieving an effect.
- 13 May 2024
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 5 (2) , 76-80
Open AccessAmiodarone-induced thyrotoxicosis type 2: the role of differential diagnosis in patient management
The antiarrhythmic drug amiodarone can affect the function of the thyroid gland, contributing to the development of thyrotoxicosis or hypothyroidism. The development of thyrotoxicosis exacerbates the cardiovascular pathology present in patients: it leads to the progression of left ventricular dysfunction, recurrence of rhythm disturbances, increasing the risk of adverse outcomes. Timely diagnosis of thyrotoxicosis in the treatment of amiodarone is of fundamental importance in choosing the right therapeutic tactics, which is determined by the type of amiodarone-induced thyrotoxicosis (AmIT), the state of the cardiovascular system, and the risk of recurrent arrhythmias. In type 1 AMIT, the main method of controlling the relief of thyrotoxicosis is thyroostatic therapy with the possibility of subsequent radical treatment (radioiodine therapy, thyroidectomy). Type 2 AmIT is a self-limiting process, however, for the treatment of patients with moderate to severe amiodarone-induced thyrotoxicosis type 2, glucocorticoids are the first-line drugs. With a mixed version of AmIT, a combination of antithyroid drugs and glucocorticoids is recommended. This review presents a clinical case of a patient with type 2 AmIT who was treated with thyrostatic drugs for a long time without achieving an effect.